Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system

Published:2022-07-20 Issue:12 Volume:88 Page:5317-5325
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Ji Chunmei¹,Bai Jinmei²,Zhou Jiancheng¹,Zou Ying¹,Yu Mingming³^ORCID

Affiliation:

1. Research Division of Clinical Pharmacology First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu China

2. Department of Respiratory Wuxi No.5 People's Hospital Wuxi Jiangsu China

3. Department of Urology Shanghai Children's Hospital, Shanghai Jiao Tong University Shanghai China

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15460

Reference30 articles.

1. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

2. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction

3. Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin‐Treated Subjects From 3 Data Sources: A Retrospective Analysis

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel insights into the association between genetically proxied inhibition of proprotein convertase subtilisin/kexin type 9 and risk of sarcopenia;Journal of Cachexia, Sarcopenia and Muscle;2024-09-10

2. Genetic Associations of Lipids and Lipid-Modifying Drug Targets With Type 2 Diabetes in the Chinese Population;JACC: Asia;2024-09

3. Safety of cardiovascular disease drugs approved between 2014 and 2021 in the US: a pharmacovigilance analysis;Expert Review of Cardiovascular Therapy;2024-05-12

4. How safe are proprotein convertase subtilisinekexin type 9 inhibitors in diabetes?;Current Opinion in Lipidology;2024-03-20

5. Adverse Reactions to Evolocumab: Analysis of Real-World Data from EudraVigilance;Pharmaceuticals;2024-03-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3